Skip to main content Skip to section navigation Skip to footer
Achieve Life Sciences, Inc. IR Overview
Achieve Life Sciences Logo
  • Home
  • About
  • Products
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Information
    • Overview
    • Management Team
    • Contacts
  • Financial Information
    • Overview
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Information
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
May 25, 2023 9:00 am EDT
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
May 23, 2023 6:00 am EDT
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
May 17, 2023 8:00 am EDT
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
May 9, 2023 4:05 pm EDT
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
Apr 26, 2023 8:00 am EDT
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
Apr 20, 2023 8:00 am EDT
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
Apr 14, 2023 8:00 am EDT
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
Mar 30, 2023 8:00 am EDT
Achieve Life Sciences Announces Refresh to Board of Directors
Mar 29, 2023 8:00 am EDT
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Mar 17, 2023 8:00 am EDT
Achieve Life Sciences Announces Granting of New Hire Inducement Award
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
  • US Headquarters
  • 22722 29th Dr SE,
    Suite 100
  • Bothell, WA 98021
  • Phone: (425) 686-1500
  • Vancouver Office
  • 1040 W Georgia Street,
    Suite 1030
  • Vancouver, BC V6E 4H1

About

  • About
  • Management Team
  • Board of Directors
  • Scientific Advisors
  • Careers

For Investors

  • Investors
  • News
  • Corporate Governance
  • Financial Information
  • SEC Filings

Recent News

April 21, 2025
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
More News

© Copyright 2025 | Achieve Life Sciences, Inc. All Rights Reserved

  • Privacy Policy
  • Disclaimer
  • Contact
  • twitter
  • linkedin